Overview
Bringing Expert Care to the Community: Precision Medicine for Pediatric and Adult Patients With SBS
Personalized Learning Platform powered by ACHL CustomED®
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start ActivityCME/CE is no longer available for this activity
Access a comprehensive review of the complex treatment of short bowel syndrome (SBS) in this robust, online content library developed by expert faculty in pediatric and adult gastroenterology and powered by ACHL CustomED®. Select content related to epidemiology, pathophysiology, and etiology of SBS; clinical manifestations and prognosis; treatment strategies and goals; treatment advances; and achievement and maintenance of enteral autonomy to customize your own slide deck. Broaden your knowledge and improve the multidisciplinary care and outcomes of patients with SBS.
This activity is intended for the multispecialty/multidisciplinary clinical team managing patients with SBS in the community practice setting.
Short bowel syndrome (SBS) is complex and can occur after major resections of the small intestine. Dietary therapy, including both parenteral and enteral nutrition, is a crucial aspect of care. Similarly, hydration is essential, and patient needs vary according to the portions of the bowel remaining. Pharmacologic management of SBS targets symptoms and enhancement of intestinal adaptation. With the availability of drugs that can promote adaptation, such as the glucagon-like peptide 2 analog teduglutide, clinicians have better tools for promoting enteral autonomy than in the past. However, managing SBS is difficult and requires a coordinated approach from multidisciplinary teams including dietitians, gastroenterologists, surgeons, nurses, social workers, and psychologists, among others. Consequently, ensuring that all clinicians have the knowledge to assist patients in progressing toward enteral autonomy and improved quality of life is a critical need underlying education in SBS.
Upon completion of this activity, participants will be able to:
• Outline dietary and drug treatment strategies for achieving and maintaining enteral autonomy and promoting intestinal absorption in diverse patients with SBS
• Describe challenges and unmet needs with parenteral nutrition and identify strategies to reduce patient dependency on parenteral support
• Implement system-based tools and best practices for providing coordinated, multidisciplinary care for patients with SBS
• Implement communication and shared decision-making strategies for patients and their caregivers to achieve enteral autonomy
• Develop individualized, state of the art SBS care plans for diverse groups of patients
• Outline dietary and drug treatment strategies for achieving and maintaining enteral autonomy and promoting intestinal absorption in diverse patients with SBS
• Describe challenges and unmet needs with parenteral nutrition and identify strategies to reduce patient dependency on parenteral support
• Implement system-based tools and best practices for providing coordinated, multidisciplinary care for patients with SBS
• Implement communication and shared decision-making strategies for patients and their caregivers to achieve enteral autonomy
• Develop individualized, state of the art SBS care plans for diverse groups of patients
Sponsored by the American Gastroenterological Association (AGA) Institute and the Academy for Continued Healthcare Learning.
Supported by an unrestricted educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Donald F. Kirby, MD
Director, Center for Human Nutrition
Medical Director, Intestinal Transplant Program
Department of Gastroenterology, Section of Nutrition
Cleveland Clinic
Cleveland, OH
Director, Center for Human Nutrition
Medical Director, Intestinal Transplant Program
Department of Gastroenterology, Section of Nutrition
Cleveland Clinic
Cleveland, OH
Samuel A. Kocoshis, MD
Professor, Pediatrics
University of Cincinnati College of Medicine, Cincinnati Children’s Hospital
Medical Director, Intestinal Transplant and Intestinal Care Center
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH
The AGA Institute requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Donald F. Kirby, MD
Advisory Board: OWYN, Inc., Takeda Pharmaceuticals, VectivBio
Samuel A. Kocoshis, MD
Advisory Board: Zealand Pharmaceuticals
Research Support: VectivBio
Speakers Bureau: Abbott Nutrition
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Proton pump inhibitors, histamine type-2 receptor antagonists, clonidine, and codeine are not indicated for the treatment of diarrhea; nitazoxanide is not indicated for the treatment of bacterial overgrowth; apraglutide, glepaglutide, HM15912, and vurolenatide are investigational therapies for the treatment of SBS. The in-line immobilized lipase cartridge is an investigational device for the treatment of pancreatic enzyme insufficiency. Nitinol springs are an investigational device for the treatment of SBS.
The AGA Institute, ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. The AGA Institute and ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.
Certificates awarding AMA PRA Category 1 Credit™ or certificates documenting participation will be issued immediately to participants when an individual completes the posttest and evaluation.
For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.
For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.
The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AGA Institute designates this enduring material for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose all their financial relationships with ineligible companies held within the past 24 months. The AGA Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.
